Abstract | BACKGROUND: METHODS: Firstly, the pcDNA3.1-NRP-1 recombinant plasmid containing neuropilin-1 (NRP1) gene and NRP1 RNA interference plasmid shRNA-NRP1 were successfully constructed. A total of 36 C57BL/6 mice were randomly assigned to 6 groups, blank group, control group, pcDNA3.1 injection group, pcDNA3.1-NRP-1 injection group, pGenesil-1.1 injection group and shRNA-NRP1 injection group. Expression of phospho-PI3K, phospho-AKT, phospho-mTOR and neuropilin-1 in liver was measured as well as body and liver weight, blood glucose, serum transaminases and lipid levels of the mice. RESULTS: The weight and liver mass of HFD fed mice injected with pcDNA3.1-NRP-1 were significantly higher than those from the control group, but their body weight and liver mass decreased significantly after shRNA-NRP1 injection. The results also showed that neuropilin-1 expression can significantly influence the severity of hepatic steatosis in HFD fed mice, decreased serum FPG, LDL, AST, ALT levels and the expression of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and IL-6 mRNA. In addition, the Neuropilin-1 expression will also influence the p-PI3K, p-AKT and p-mTOR in mice. CONCLUSIONS: This study concluded that the inhibition of neuropilin-1 could improve NAFLD disease by decreasing body weight and reduce inflammation in HFD induced obese mice by modulating the PI3K/AKT/mTOR signaling pathway.
|
Authors | Jian Zhou, Sian Xu, Yue Zhu, Xin Li, Ao Wang, Junfang Hu, Li Li, Yan Liu |
Journal | Minerva endocrinology
(Minerva Endocrinol (Torino))
Vol. 48
Issue 2
Pg. 194-205
(Jun 2023)
ISSN: 2724-6116 [Electronic] Italy |
PMID | 36285747
(Publication Type: Journal Article)
|
Chemical References |
- Neuropilin-1
- Proto-Oncogene Proteins c-akt
- Phosphatidylinositol 3-Kinases
- TOR Serine-Threonine Kinases
|
Topics |
- Mice
- Animals
- Non-alcoholic Fatty Liver Disease
(etiology, metabolism)
- Mice, Obese
- Neuropilin-1
(genetics)
- Proto-Oncogene Proteins c-akt
- Phosphatidylinositol 3-Kinases
- Mice, Inbred C57BL
- Diet, High-Fat
(adverse effects)
- Obesity
- TOR Serine-Threonine Kinases
|